About agalsidase alfa
Enzyme replacement therapy
Used for
- Treats Fabry disease by replacing deficient alpha-galactosidase A.
Usual adult dose
0.2 mg/kg by intravenous infusion every two weeks.
Usual dose in children
0.2 mg/kg by intravenous infusion every two weeks; used in children aged seven years and older.
Common side effects
- Infusion-related reactions, including chills, fever, headache, nausea, or flushing
- Pain in limbs or chest
- Nasal congestion or sore throat
- Allergic reactions, rarely severe
Important warnings
- Administer by infusion under medical supervision.
- Infusion reactions may require slowing or stopping the infusion.
- Antibodies to the medicine can develop and may affect response.
- Use caution with significant heart disease or previous severe infusion reactions.
Pregnancy
Limited human data; use during pregnancy only when clearly needed after medical assessment.
Breastfeeding
Unknown whether it passes into breast milk; weigh treatment benefits against potential risks.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.